James E. Flynn - Insider Trading & Ownership

Entity
Individual
Location
780 Third Avenue, 37 Th Floor, New York, NY
Summary
The estimated net worth of James E. Flynn is at least $2.44B dollars as of November 13, 2024. James E. Flynn is the Director, * Director by deputization, 10%+ Owner of Nuvalent, Inc. and owns shares of Nuvalent, Inc. (NUVL) stock worth about $1.76B. James E. Flynn is the 10%+ Owner of ARS Pharmaceuticals, Inc. and owns shares of ARS Pharmaceuticals, Inc. (SPRY) stock worth about $187M. James E. Flynn is the Director, * Director by Deputization, 10%+ Owner of Larimar Therapeutics, Inc. and owns shares of Larimar Therapeutics, Inc. (LRMR) stock worth about $186M. James E. Flynn is the *Possible Member of 10% Group, 10%+ Owner of AdaptHealth Corp. and owns shares of AdaptHealth Corp. (AHCO) stock worth about $142M. James E. Flynn is the * Possible Member of 10% Group, 10%+ Owner of Mirum Pharmaceuticals, Inc. and owns shares of Mirum Pharmaceuticals, Inc. (MIRM) stock worth about $91M. James E. Flynn is the Director, Director by Deputization, 10%+ Owner of CareMax, Inc. and owns shares of CareMax, Inc. (CMAX) stock worth about $54.7M. James E. Flynn is the Director, *Director by Deputization of BiomX Inc. and owns shares of BiomX Inc. (PHGE) stock worth about $6.81M. James E. Flynn is the Director, Director by Deputization, 10%+ Owner of Acutus Medical, Inc. and owns shares of Acutus Medical, Inc. (AFIB) stock worth about $4.16M. James E. Flynn is the Possible Member of 10% Group, 10%+ Owner of PepGen Inc. and owns shares of PepGen Inc. (PEPG) stock worth about $3.97M. James E. Flynn is the *Possible Member of 10% Group, 10%+ Owner of Singular Genomics Systems, Inc. and owns shares of Singular Genomics Systems, Inc. (OMIC) stock worth about $3.86M. James E. Flynn is the Possible Members of 10% Group, 10%+ Owner of Fractyl Health, Inc. and owns shares of FRACTYL HEALTH, INC. (GUTS) stock worth about $2.42M. James E. Flynn is the Possible Member of 10% Group, 10%+ Owner of Xilio Therapeutics, Inc. and owns shares of Xilio Therapeutics, Inc. (XLO) stock worth about $1.9M.
All Insider Reports
All Insider Reports

Ownership of James E. Flynn

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
NUVL Nuvalent, Inc. Director, * Director by deputization, 10%+ Owner $1.76B -$196M -10% Oct 22, 2024
SPRY ARS Pharmaceuticals, Inc. 10%+ Owner $187M -$10.1M -5.15% Nov 11, 2024
LRMR Larimar Therapeutics, Inc. Director, * Director by Deputization, 10%+ Owner $186M +$37.5M +25.3% May 29, 2024
AHCO AdaptHealth Corp. *Possible Member of 10% Group, 10%+ Owner $142M -$3.82M -2.62% Mar 8, 2024
MIRM Mirum Pharmaceuticals, Inc. * Possible Member of 10% Group, 10%+ Owner $91M Jun 6, 2022
CMAX, CMAXW CareMax, Inc. Director, Director by Deputization, 10%+ Owner $54.7M Nov 17, 2023
PHGE BiomX Inc. Director, *Director by Deputization $6.81M Jul 15, 2024
AFIB Acutus Medical, Inc. Director, Director by Deputization, 10%+ Owner $4.16M Jun 30, 2022
PEPG PepGen Inc. Possible Member of 10% Group, 10%+ Owner $3.97M May 10, 2022
OMIC Singular Genomics Systems, Inc. *Possible Member of 10% Group, 10%+ Owner $3.86M Jun 1, 2021
GUTS FRACTYL HEALTH, INC. Possible Members of 10% Group, 10%+ Owner $2.42M Feb 6, 2024
XLO Xilio Therapeutics, Inc. Possible Member of 10% Group, 10%+ Owner $1.9M Oct 26, 2021
BCAX Bicara Therapeutics Inc. Possible Members of 10% Group, 10%+ Owner Sep 17, 2024
FLAC Frazier Lifesciences Acquisition Corp Possible Member of 10% Group, 10%+ Owner Nov 8, 2022
TOI, DFPH Oncology Institute, Inc. Possible Members of 10% Group, 10%+ Owner Nov 12, 2021
ONCR Oncorus, Inc. Possible Member of 10% Group, 10%+ Owner Dec 28, 2022

Insider Transactions Reported by James E. Flynn:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.